Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...
Posted by Michael Wonder on 04 Nov 2023
Elexacaftor with tezacaftor and ivacaftor, tezacaftor with ivacaftor and lumacaftor with ivacaftor for the treatment of patients with cystic fibrosis
3 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Empagliflozin for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
1 November 2023 - NICE has published final evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 31 Oct 2023
NICE launches first modular update to its methods and processes
31 October 2023 - NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of ...
Posted by Michael Wonder on 26 Oct 2023
Olipudase alfa for the treatment of patients with acid sphingomyelinase deficiency (Niemann-Pick disease type B and AB)
26 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Oct 2023
First NICE recommended treatment for Parkinson’s set to benefit hundreds
26 October 2023 - Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved ...
Posted by Michael Wonder on 25 Oct 2023
Baricitinib for the treatment of patients with severe alopecia areata (update)
25 October 2023 - NICE has published final evidence-based recommendations on the use of baricitinib (Olumiant) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Mirikizumab for the treatment of patients with moderate to severe active ulcerative colitis
25 October 2023 - NICE has published final evidence-based recommendations on the use of mirikizumab (Omvoh) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Tirzepatide for the treatment of patients with type 2 diabetes mellitus
25 October 2023 - NICE has published final evidence-based recommendations on the use of tirzepatide (Mounjaro) for the treatment of ...
Posted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 19 Oct 2023
Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus
19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...
Posted by Michael Wonder on 19 Oct 2023
Daridorexant hydrochloride for the treatment of patients with long-term insomnia
18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the ...